Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
News provided by
Share this article
Share this article
DUBLIN, May 5, 2021 /PRNewswire/ Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ( GW ), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint, said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are complementary to our existing business, including
Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021
DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the following virtual investor conferences:
BofA Securities 2021 Health Care Conference on Tuesday, May 11, 2021 at 1:15 p.m. ET / 6:15 p.m. IST
RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 10:40 a.m. ET / 3:40 p.m. IST
UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 11:00 a.m. ET / 4:00 p.m. IST
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcast will be archived on the website for at least one week.
Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Continued Zepzelca Growth Across Second-Line SCLC Setting
Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date
On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader
Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition
23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020
2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion
DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.